ClinicalTrials.gg
RecruitingNCT05803785Updated May 15, 2026

Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

A Phase 1 interventional study of BBC1501 in Age-Related Macular Degeneration, sponsored by Benobio Co., Ltd.. Recruiting at 2 sites in Australia. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Benobio Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Macular Degeneration with a site in Australia — 17 open to participants now, 22 under way, 7 of them phase 3. Macular Degeneration · Australia.

Planned enrollment
61st of 66
18 · median 280
Started
2025
with 7 others
Phase 1
5 of 77
1 open now
Primary completion
2026-12
later than 1 of 21 live
Registered
60th of 77
by date

Among the 77 studies in Macular Degeneration with a site in Australia, this one is the 61st largest by planned enrollment of the 66 interventional ones that give a count, is one of 8 that started in 2025, is one of 5 in phase 1, reaches primary completion later than 1 of the 21 other live ones, and was the 60th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

17 of the 77 studies in Macular Degeneration with a site in Australia are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Macular Degeneration with a site in Australia, or all of them as a file.
02

Study summary

This open-label study is being conducted to evaluate the initial safety and tolerability of BBC1501 IVT in patients with nAMD. The primary objective of this study is to evaluate the safety and tolerability of 3 ascending doses of IVT BBC1501 in patients with nAMD. The secondary objective of this study is to exploratory of BBC1501 efficacy following 3 ascending dose of BBC1501 in nAMD patient.

03

Conditions studied

  • Age-Related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Able to provide voluntary written on the approved ICF, understand the study requirements, and are willing to follow and complete all the study required procedures.
  • Male or female aged ≥ 50 years.
  • As per the Investigator's judgment, patients with active CNV lesions (ie, foveal or parafoveal) secondary to nAMD, as confirmed with SD-OCT, FFA, and fundus photography (FP) in the study eye. Patients must have received at least two prior anti-VEGF doses (eg, aflibercept, ranibizumab, bevacizumab, brolicizumab, or faricimab), meeting criteria for non-ideal response
  • Active CNV lesions, secondary to nAMD as confirmed with SD-OCT (or SS-OCT), FFA and fundus photography (FP) in the study eye.
  • BCVA score of between 73 and 21 letters, inclusive, in the study eye using ETDRS testing (Snellen equivalent score between 20/40 and 20/400, inclusive
  • Participant has CST > 250 μm if measured by Cirrus OCT or > 270 μm if measured by Spectralis OCT, with presence of intraretinal and/or subretinal fluid
  • Participants who have had a of at least six weeks prior to first administration of the IMP for any IVT anti-VEGF medication and, who in the opinion of the investigator, have disease sufficiently stable to enable this interval.

Key Exclusion Criteria:

  • Use of any of the following treatments or anticipated use of any of the following treatments to the study eye:
  • Intravitreal or periocular , within 90 days prior to Visit 1 (Day 1) and throughout the study.
  • Glaucoma, evidenced by an IOP of > 21 mmHg despite up to 4 glaucoma medications, or evidence of glaucomatous visual field loss or has advanced glaucoma (e.g., prior shunt surgery) in either eye
  • Evidence of any other ocular disease other than nAMD in the study eye that may confound the outcome of the study (eg, active diabetic retinopathy, posterior uveitis, pseudovitelliform macular degeneration, moderate/severe myopia).
  • Participants with advanced nAMD and no prognosis of BCVA as per Investigator's judgement (e.g. due to macular OCT signs of atrophy or photoreceptors disruption, or macular/foveal subretinal hemorrhage).
  • Need for ocular surgery in the study eye during the course of the study.
  • YAG laser capsulotomy within 30 days prior to Visit 1 in the study eye.
  • Intraocular surgery, including lens removal or laser, within 90 days prior to Visit 1 in the study eye.
  • Ocular or periocular infection in either eye.
  • Pupillary dilation inadequate for quality stereoscopic fundus photography in the study eye.
  • Media opacity that would limit clinical visualization, intravenous fluorescein angiography, or spectral-domain optical coherence tomography (SD-OCT) evaluation in the study eye.
  • History of herpetic infection in the study eye or adnexa.
  • Presence of known active toxoplasmosis, inactive toxoplasmosis or toxoplasmosis scar in either eye.
  • Presence of any form of ocular including choroidal melanoma in either eye
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    BBC1501 1.25ug

    Cohort 1; open-label, non-randomized, single administration

    Drug: BBC1501

  • Experimental
    BBC1501 2.5ug

    Cohort 2; open-label, non-randomized, single administration

    Drug: BBC1501

  • Experimental
    BBC1501 5ug

    Cohort 3; open-label, non-randomized, single administration

    Drug: BBC1501

Interventions

  • DrugBBC1501

    BBC1501 solution for Intravitreal injection

06

What researchers measure

Primary outcomes

  1. Assessment of ophthalmic and systemic TEAEs, during study period

    To evaluate the safety and tolerability of a single IVT dose of BBC1501 at 4 weeks after dose.To characterize ocular and non-ocular safety by the incidence of treatment-emergent adverse events (AEs) (new or worsening from baseline) summarized categorically by system organ class and/or preferred term.

    Time frame: Every week up to 4 weeks

  2. Assessment of ophthalmic and systemic TEAEs, during study period

    To evaluate the safety and tolerability of a single IVT dose of BBC1501 at 12 weeks after dose.To characterize ocular and non-ocular safety by the incidence of treatment-emergent adverse events (AEs) (new or worsening from baseline) summarized categorically by system organ class and/or preferred term.

    Time frame: every 4 weeks up to 12 weeks

Secondary outcomes

  1. Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA from baseline

    Assessment ETDRS change from baseline by Optical Coherence Tomography(OCT)

    Time frame: Baseline, Week4

  2. Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA from baseline

    Assessment ETDRS change from baseline by Optical Coherence Tomography(OCT)

    Time frame: Baseline, Week12

  3. Number of patients who initiation of rescue therapy during study

    Exploratory using rescue therapy during study and follow-up period

    Time frame: Week1, Week12

Other outcomes

  1. Change in CNV size according to fluorescein angiogram

    Assessment CNV size change from baseline by Fundus fluorescein angiography(FFA)

    Time frame: Baseline, Week4

  2. Change in CNV size according to fluorescein angiogram

    Assessment CNV size change from baseline by Fundus fluorescein angiography(FFA)

    Time frame: Baseline, Week12

  3. Changes in intra-or sub-retinal fluid measured as mean change in central retinal thickness or macula volume

    Assessment Central retinal thickness from baseline by Spectral Domain Optical Coherence Tomography (SD-OCT)

    Time frame: Baseline, Week4

  4. Changes in intra-or sub-retinal fluid measured as mean change in central retinal thickness or macula volume

    Assessment Central retinal thickness from baseline by Spectral Domain Optical Coherence Tomography (SD-OCT)

    Time frame: Baseline, Week12

07

Study locations

1 of 2 sites recruiting
  • Benobio Investigational site
    Sydney, New South Wales 2000, Australia
    Not yet recruiting
  • Sydney Hospital
    Sydney, Australia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's planned 17 months is above that.

Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2023
First posted
Apr 7, 2023
StartActual
Jul 1, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05803785
Lead sponsor
Benobio Co., Ltd.
Responsible party
Sponsor
First posted
Apr 7, 2023
Start date
Jul 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 15, 2026

Study contacts

jihye choe
Contact
jihye.choe@benobio.com
+827046675278
Inhyun Lee, ph.D
study chair · Benobio Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion